(Reuters Health)—People with psychiatric illnesses are more likely to have complications after hip replacement surgery, according to a recent analysis. This added risk is something doctors and patients should discuss in advance, the study team writes in The Journal of Arthroplasty, March 17. Previous studies have linked depression and other mental illnesses to greater complications…
Articles by Natasha Yetman
Ryan Wants to End Obamacare Cost Protections for Sick Consumers
WASHINGTON (Reuters)—U.S. House of Representatives Speaker Paul Ryan (R-Wis.) called on Wednesday for an end to Obamacare‘s financial protections for people with serious medical conditions, saying these consumers should be placed in state high-risk pools. In election-year remarks that could shed light on an expected Republican healthcare alternative, Ryan said existing federal policy that prevents…
Triple Therapy with Methotrexate Effective, Cheaper in RA
NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…
Abaloparatide May Boost BMD in Older Women with Osteoporosis
NEW YORK (Reuters Health)—The investigational drug abaloparatide may help postmenopausal women increase their bone mineral density (BMD) and reduce their risk of fracture, new industry research suggests. “What was surprising and very important about this study was that, although some drugs for osteoporosis don’t work across all patient subgroups, abaloparatide provided persistent protection against fracture…
CMS Commences 45-Day Open Payments Review & Dispute Period
On April 1, the Centers for Medicare and Medicaid Services (CMS) announced the beginning of the 45-day Open Payments Review and dispute period, which will conclude on May 15. After the review period concludes, on June 30, CMS will publish 2015 payment data along with updates to the 2013 and 2014 data. If you are…
Sifalimumab Shows Some Promise Against Lupus
NEW YORK (Reuters Health)—Sifalimumab, an anti-interferon alpha monoclonal antibody, may lead to some improvement in patients with systemic lupus erythematosus (SLE), according to a new trial. In a paper online on March 23 in Annals of the Rheumatic Diseases, Dr. Munther Khamashta of King’s College London and colleagues note that treatment of SLE presents a…
Hidradenitis Suppurativa Can Complicate Biologic Therapy
NEW YORK (Reuters Health)—Hidradenitis suppurativa can complicate biologic therapy of chronic inflammatory diseases, according to a retrospective study from France and Belgium. Hidradenitis suppurativa (HS) often responds to treatment with biologic agents, but there have been scattered reports of patients developing HS while undergoing biologic therapy. Dr. Coline Faivre from Hôpital Edouard Herriot in Lyon,…
U.S., Canada Issue Joint Alert on Ransomware after Hospital Attacks
(Reuters)—The U.S. and Canada on Thursday issued a rare joint cyber alert, warning against a recent surge in extortion attacks that infect computers with viruses known as “ransomware,” which encrypt data and demand payments for it to be unlocked. The warning follows reports from several private security firms that they expect the crisis to worsen,…
U.S. to Raise Payments to Insurers for Medicare Advantage 2017 Plans
NEW YORK (Reuters)—U.S. health insurers that provide Medicare Advantage plans to elderly and disabled Americans will receive government payments in 2017 that are 0.85 percent higher on average than in 2016, reflecting small anticipated growth in medical costs, the U.S. Department of Health and Human Services said on Monday. Health and Human Services’ final plan…
Remicade Antibodies Cross-React to Biosimilars
NEW YORK (Reuters Health)—Patients with antibodies to infliximab in Remicade should not be switched to biosimilars, researchers warn. “(The) antibodies will cross-react with the new biosimilar drug, potentially reducing clinical response,” Dr. Daniel Nagore, director of research and development at Progenika Biopharma in Derio, Spain, told Reuters Health by email. “The study highlights the importance…
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 97
- Next Page »